FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, in particular to new oligonucleotide; it can be used in medicine. The invention discloses oligonucleotide providing passage of two or more exons into dystrophin pre-mRNA due to its capability of binding to a region of the specified exons in the same pre-mRNA.
EFFECT: invention can be used in the treatment of hereditary diseases: Becker muscular dystrophy (BMD) or Duchenne muscular dystrophy (DMD).
8 cl, 5 ex, 6 tbl, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTANCES FOR TARGETING VARIOUS SELECTED ORGANS OR TISSUES | 2017 |
|
RU2759022C2 |
| OLIGONUCLEOTIDES SWITCHING OR MODULATING PRE-RNA SPLICING AND CONTAINING BICYCLIC FRAMEWORK FRAGMENTS WITH IMPROVED CHARACTERISTICS FOR TREATING GENETIC DISEASES | 2017 |
|
RU2769249C2 |
| THERAPY METHODS BASED ON CAR T-CELLS WITH INCREASED EFFICIENCY | 2016 |
|
RU2788131C2 |
| ANTISENSE NUCLEIC ACIDS | 2015 |
|
RU2825834C2 |
| HSD17B13 OPTIONS AND THEIR APPLICATIONS | 2018 |
|
RU2760851C2 |
| COMPOSITIONS AND METHODS FOR REDUCING TAU EXPRESSION | 2016 |
|
RU2747734C2 |
| COMPOSITIONS AND METHODS FOR REDUCING TAU EXPRESSION | 2016 |
|
RU2777570C2 |
| BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING | 2019 |
|
RU2819149C2 |
| MODIFIED OLIGONUCLEOTIDES AND METHODS OF THEIR USE | 2017 |
|
RU2802836C2 |
| COMPOUND FOR MODULATION OF C9ORF72 GENE EXPRESSION AND USE THEREOF | 2013 |
|
RU2730677C2 |
